Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

Potential role of AQP1 and VEGF in the development of malignant pleural effusion in mice

Authors: Jing Xuan Zhang, C. M. Xie, Z. W. Zhu, H. Y. Huang, Z. L. Zeng

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

Recent studies have revealed the important role of aquaporin-1 (AQP1) in tumor cell migration and angiogenesis. However, the function of AQP1 in malignant pleural effusion has not been well characterized. We established a mouse model to examine the role of AQP1 and vascular endothelial growth factor (VEGF) in the development of malignant pleural effusion. We showed that elevated expressions of AQP1 mRNA and VEGF protein were associated with increased volume of malignant pleural effusion. These results suggest that AQP1 and VEGF play important roles in the development of malignant pleural effusion in mice, which may help us find new strategies for the prevention and treatment of malignant pleural effusion.
Literature
1.
Waterhouse JAH, Muir C, Correa P, Powell J, editors. Cancer incidence in five continents, vol. III. Lyon: IARC Scinetific; 1976. p. 504–7.
2.
Muir C, Waterhouse JAH, Mack TM, Powell J, Whelan S. Cancer incidence in five continents, vol. V. Lyon: IARC Scientific Publications; 1987. p. 868–9.
3.
Blot WJ, Fraumeni JR Jr. Cancers of the lung and pleura. In: Schottenfeld D, Faumeni Jr. JF, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 1996. p. 637–65.
4.
Prehn A, et al. Cancer incidence in Chinese, Japanese and Filipinos in the US and Asia 1988–1992. Union City, CA: Northern California Cancer Center; 1999. p. 34–5.
5.
6.
Yilong W. Multidisciplinary therapy theory and practice of lung cancer, vol. 1. Beijing, China: People’s Health Publishing House; 2000. p. 277.
7.
Song Y, Yang B, Matthay MA, Ma T, Verkman AS. Role of aquaporin water channels in pleural fluid dynamics. Am J Physiol Cell Physiol. 2000;279(6):C1774–5.
8.
Borok Z, Verkman AS. Lung edema clearance: 20 years of progress: invited review: role of aquaporin water channels in fluid transport in lung and airways. J Appl Physiol. 2002;93:2199–206.PubMed
9.
Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusions formation. Oncologist. 2000;5(Suppl 1):45–50.PubMedCrossRef
10.
Yano S, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6(3):957–65.PubMed
11.
Yanagawa H, et al. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother. 1999;48(7):396–400.PubMedCrossRef
12.
Yano S, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157(6):1893–903.PubMedCrossRef
13.
14.
Matsuyama W, et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest. 2000;118(4):948–51.PubMedCrossRef
15.
Dender BM, Smith BL, Kuhajda FP, Agre P. Identification, purification and partial characterization of a novel Mr 28, 000 integral membrane protein from erythrocytes and renal tubules. J Biol Chem. 1988;263(30):15634–42.
16.
Agre P, Sasaki S, Chrispeels MJ. Aquaporins: a family of water channel proteins. Am J Physiol. 1993;265(3 Pt 2):F461.PubMed
17.
Yang B. The human aquaporin gene family. Curr Genomics. 2000;1(1):91–102.CrossRef
18.
Verkman AS. Physiological importance of aquaporin water channels. Ann Med. 2002;34(3):192–200.PubMed
19.
Hatakeyama S, et al. Cloning of a new aquaporin (AQP10) abundantly expressed in duodenum and jejunum. Biochem Biophys Res Commun. 2001;287(4):814–9.PubMedCrossRef
20.
Benga G, et al. Water permeability inhuman erythrocytes: identification of membrane proteins involved in water transport. Eur J Cell Biol. 1986;41(2):252–62.PubMed
21.
22.
23.
Zhang W, Xie CM, Huang JQ, Liao H, Ke CX. Effect of hypertonic medium on expression of aquaporin-1 in pleural mesothelial cells: experiment with rats. Zhonghua Yi Xue Za Zhi. 2007;87(35):2508–11.PubMed
24.
Zhang W, Xie CM, Ke CX. Effect of dexamethasone on the expression of aquaporin-1 in cultured rat pleural mesothelial cells. Chinese Journal of Pathophysiology. 2007;23(1):22–6.
25.
Saadoun S, Papadopoulos MC, Davies DC, Bell BA, Krishna S. Increased aquaporin-1 water channel expression in human brain tumors. Br J Cancer. 2002;87(6):621–3.PubMedCrossRef
26.
Nagashima G, et al. Dural invasion of meningioma: a histological and immunohistochemical study. Brain Tumor Pathol. 2006;23:13–7.PubMedCrossRef
27.
Longatti P, Basaldella L, Orvieto E, Dei Tos A, Martinuzzi A. Aquaporin(s) expression in choroids plexus tumours. Pediatr Neurosurg. 2006;42(4):228–33.PubMedCrossRef
28.
Xiang Y, Ma B, Li T, Yu HM, Li XJ. Acetazolamide suppresses tumor metastasis and related protein expression in mice bearing Lewis lung carcinoma. Acta Pharmacol Sin. 2002;23(8):745–51.PubMed
29.
Ma B, Xiang Y, Li T, Yu HM, Li XJ. Inhibitory effect of topiramate on Lewis lung carcinoma metastatis and its relation with AQP1 water channel. Acta Pharmacol Sin. 2004;25(1):54–60.PubMed
30.
Mohammed KA, et al. Mycobacteria induces pleural mesothelial permeability by down-regulating beta-catenin expression. Lung. 2003;181(2):57–66.PubMedCrossRef
31.
Yano S, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157:1893–903.PubMedCrossRef
32.
Strizzi L, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193(4):468–75.PubMedCrossRef
33.
Yeo KT, et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 1993;53:2912–8.PubMed
34.
Endo M, Jain RK, Witwer B, Brown D. Water channel (aquaporin-1) expression and distribution in mammary carcinomas and glioblastomas. Microvasc Res. 1999;58(2):89–98.PubMedCrossRef
35.
Xiefei Q. Lung cancer and anti-angiogenic gene therapy. Int J Respir (Chinese). 2000;20(4):193–5.
36.
Zhengang Ren, Youxin Jin. Observation of antisense ligonucleotide of vascular endothelial growth factor’s in inhibiting human hepatocellular carcinoma in nude mice. National Med J China. 1999;79(1):65–8.
37.
McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2005;4:641–9.PubMedCrossRef
Metadata
Title
Potential role of AQP1 and VEGF in the development of malignant pleural effusion in mice
Authors
Jing Xuan Zhang
C. M. Xie
Z. W. Zhu
H. Y. Huang
Z. L. Zeng
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9960-6

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue

Case Report

Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma

Original Paper

MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma

Short Communication

Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better

Original Paper

Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients

Case Report

Primary malignant melanoma of the penis: a case report

Original Paper

Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits